If the global pharmaceutical cannabis market only grows, the challenges here still involve bias and late regulation.
While the global pharmaceutical cannabis market grows by leaps and bounds, Brazil is still experiencing a reality in which less than 1% of doctors prescribe treatment for their patients.
Whether due to a lack of knowledge of published scientific evidence, or even to deep-seated prejudices, this fact culminates in difficulties in the accessibility of this therapy to patients and, of course, has worried Brazilian entrepreneurs in the sector.
Among these Fabrizio Postiglione, current CEO of ReMederi: “I experienced the approval of pharmaceutical cannabis in the United States in 2018 and, the following year, I returned to Brazil to experience this story here, which still has everything to give it my all . I compare the approval of cannabis products to the Internet boom: a $ 315 million market with everything to take off. “
In a chat with the entrepreneur Rodrigo Guerra a this podcast from the Unbox Project, Postiglione also tells the details on the creation of ReMederi and how the company has been part of his family’s history, as well as, of course, the debate on the future of the sector.
Renata Armas is a writer forunbox
.
Source: Terra
Benjamin Smith is a fashion journalist and author at Gossipify, known for his coverage of the latest fashion trends and industry insights. He writes about clothing, shoes, accessories, and runway shows, providing in-depth analysis and unique perspectives. He’s respected for his ability to spot emerging designers and trends, and for providing practical fashion advice to readers.
